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Introduction
Variant Creutzfeldt-Jakob disease (vCJD) is a zoonotic prion disease thought to have been
transmitted to humans through the consumption of food products contaminated with bovine
spongiform encephalopathy (BSE) in the 1980s and/or early 1990s. As with all prion disorders,
it is a fatal neurodegenerative disease arising from conversion of the normal cellular form of
the prion protein PrPC, encoded by the prion gene (PRNP), to an abnormal form associated
with disease (PrPSc). Prion diseases have long asymptomatic incubation periods ranging from
years to decades. Extensive studies involving both natural and experimental animal diseases
have demonstrated that infectivity is present during the subclinical phase and may be trans-
mitted between individuals. While the cases of clinical vCJD currently appear to be in decline,
one of the current challenges is defining the prevalence of subclinical disease and the risk this
poses to both individuals and the general population.
1. vCJD: Current perspective
In 1996, the first cases of vCJD were identified through systematic surveillance in the United
Kingdom in collaboration with other European countries. vCJD typically occurs in young
adults, and susceptibility is associated with the codon 129 polymorphism of PRNP (methionine
[M]/valine [V]), with 177 out of 178 clinical cases being 129MM [1]. However, experimental
transmission studies indicate that all genotypes may be susceptible and that 129MV and
129VV individuals may have long asymptomatic incubation periods [2]. Although the annual
number of deaths due to vCJD peaked in 2000 with 28 deaths, this has since decreased, with
only two deaths since 2011; one in 2013, and one in 2016 [1]. However, the latest case, in 2016,
is the first instance of probable and/or definite clinical vCJD in a 129MV individual, raising
concerns that a second wave of vCJD may occur in individuals of this genotype [1].
In addition to primary cases, thought to be directly acquired from BSE, three clinical cases
of vCJD have been identified in 129MM individuals who had received nonleucoreduced red
cell concentrates from UK donors who were asymptomatic at the time of donation but later
died of vCJD. In addition, evidence of subclinical infection has been found in two other indi-
viduals, both of whom had a 129MV genotype [3]. One of these asymptomatic individuals
showed no evidence of PrPSc in the brain, but evidence of PrPSc was identified in the spleen
and a cervical lymph node [4]. Bioassay of the spleen material in wild-type and transgenic
mice expressing human PrP (129MM) confirmed that the spleen carried vCJD infectivity
(Table 1) [5]. Additional studies that have utilised protein misfolding cyclic amplification
(PMCA; a protein amplification technique analogous to PCR that measures prion seeding
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006642 November 30, 2017 1 / 5
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Diack AB, Will RG, Manson JC (2017)
Public health risks from subclinical variant CJD.
PLoS Pathog 13(11): e1006642. https://doi.org/
10.1371/journal.ppat.1006642
Editor: Heather L. True, Washington University
School of Medicine, UNITED STATES
Published: November 30, 2017
Copyright: © 2017 Diack et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Funding: The Roslin Institute receives funding
from the Biotechnology and Biological Sciences
Research Council (BBSRC) (BB/J004332/1). The
Diack and Manson laboratories are also funded by
the National Institute for Health Research (NIHR)
Policy Research Programme [Strain typing of
vCJD; 007/0195]. The views expressed in this
publication are those of the author(s) and not
necessarily those of the NHS, the NIHR, the
Department of Health, ‘arms’ length bodies, or
other government departments. The funders had
no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing interests: The authors have declared
that no competing interests exist.
activity) have also provided evidence of widespread prion seeding activity in a range of tissues
in the asymptomatic 129MV individual (Table 1) [6].
2. Abnormal PrP and transmission potential
Understanding the association between the presence of PrPSc and infectivity is essential in
order to estimate disease prevalence and manage transmission risks. Retrospective appendix
studies have indicated that 1 in 2,000 individuals have evidence of abnormal PrP in the appen-
dix. The first studies of paraffin-embedded appendixes from preclinical vCJD patients demon-
strated that abnormal PrP can be detected at least two years before clinical symptoms become
apparent [7]. The first retrospective study reported a prevalence of approximately 1 in 4,000
individuals with abnormal PrP in their appendixes; of the three positive specimens identified,
two were 129VV (Table 2) [8,9]. Two larger studies were subsequently performed. Appendix
II and III both found a prevalence of approximately 1 in 2,000. Appendix II identified 16 posi-
tive samples that included a higher proportion of 129VV when compared with the normal
population distribution and confirmed clinical cases of vCJD (Table 2) [10]. Appendix III was
Table 1. Tissues identified as containing abnormal PrP and/or infectivity in clinical and subclinical vCJD patients.
Tissue Clinical vCJD patients (129MM) Subclinical vCJD patient (129MM) Subclinical vCJD patient (129MV)
Frontal cortex +1, 2, 3 +1,3 -2
Pituitary gland +1 ND +2
Cervical lymph node +1, 2 ND +1, 2
Tonsil +1, 2, 3 ND +2
Appendix +1, 2 +1 +2
Distal ileum +1, 2 ND +2
Spleen +1, 2, 3 ND +1, 2, 3
Thymus +1 ND +2
Lung +2 ND +2
Heart +2 ND -2
Liver +1, 2 ND +2
Kidney +1, 2 ND -2
Salivary gland +2 ND +2
Pancreas +1, 2 ND -2
Thyroid +2 ND -2
Adrenal gland +1, 2 ND -2
Bone marrow +2 ND -2
Skeletal muscle +1, 2 ND -2
Optic nerve +1 ND ND
Testis +2 ND ND
Ovary +1, 2 ND ND
Rectum +1 ND ND
Retina +1 ND ND
Skin +1 ND ND
Uterus +1 ND ND
Blood (plasma) +2 +2 ND
Abnormal PrP and/or infectivity measured by immunohistochemistry/biochemical analysis,1 PMCA,2 or infectivity3 studies. Data compiled from [4–7,18–20].
+, positive; -, negative.
Abbreviations: M, methionine; ND, no data; PMCA, protein misfolding cyclic amplification; PrP, prion protein; V, valine; vCJD, variant Creutzfeldt-Jakob
disease.
https://doi.org/10.1371/journal.ppat.1006642.t001
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conducted on specimens that had been removed either prior to the BSE crisis or from individ-
uals who were born in 1996 or later, at a time when food safety measures had been fully imple-
mented. In this study, seven specimens containing abnormal PrP deposits were identified
(Table 2) [11], and this raises questions about the interpretation of the abnormal PrP in rela-
tion to vCJD infection, particularly in those cohorts with presumably limited exposure to BSE.
It is uncertain whether the positive immunohistochemical staining observed is vCJD specific,
although such staining has not been observed in sporadic Creutzfeldt-Jakob disease (sCJD)
[12]. One interpretation is that the period of human exposure to BSE was more extended than
previously thought. These considerations are important for public health because individuals
subclinically infected with vCJD may have the potential to transmit disease to others [8–10].
3. Subclinical prion disease
Subclinical disease is a well-studied phenomenon in prion diseases. Animal models demon-
strate that during a long asymptomatic period, the level of infectivity increases in peripheral
and central nervous system (CNS) tissue well before the onset of clinical disease [13]. During
this period, infected tissues pose a risk of onward transmission, for example in humans via tis-
sue transplant, contaminated surgical instruments, or infected blood.
A number of animal studies have investigated blood as a route of transmission of prion dis-
ease [3]. Seminal studies in sheep models of prion disease demonstrated that BSE could be
transmitted via blood transfusion [14]. Further studies demonstrated that all blood compo-
nents were capable of transmitting disease during the subclinical period [15]. The blood-trans-
fusion–related human cases demonstrate that individuals of the 129MM genotype can
transmit infectivity prior to developing clinical signs of disease.
Although the blood-transfusion–related cases of vCJD provide evidence of subclinical
transmission, we still do not know at which point and in which tissues individuals first become
infectious nor whether this will vary between codon 129 genotypes. Assessing the risk of iatro-
genic transmission associated with subclinical vCJD is required to ascertain the potential for
the transmission of disease between individuals.
Table 2. Summary of the appendix survey results.
Study No. of positive samples Birth cohort Appendix removal period Codon 129 genotype Sex
Appendix I [8,9] 3/12,674 - 1995–2000 VV (2) -
Appendix II [10] 16/21,441 1941–1945 2000–2012 MM M
1946–1950 MM M
1951–1955 MM M
1956–1960 MV
VV (2)
M
F (2)
1966–1970 VV (2)
MV
F (2)
M
1971–1975 MV
MV
M
F
1976–1980 MM (3) M (3)
1981–1985 MM
MM
M
F
Appendix III [11] 2/5,865 - 1977–1979 - -
5/10,074 1996–2000 2000–2014 - -
-, no data.
Abbreviations: MM, methionine homozygous; MV, methionine/valine; VV, valine homozygous.
https://doi.org/10.1371/journal.ppat.1006642.t002
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4. Detecting subclinical disease
Although abnormal PrP can be detected by immunohistochemistry or seeding activity in a
number of tissues from asymptomatic individuals, blood or urine are the only practicable sub-
strates for the premortem identification of infected individuals [6]. A number of tests with
varying specificity and sensitivity have been developed in order to detect vCJD infection by
using blood or plasma from vCJD patients [16,17]. Recently, a test utilising a combination of a
plasminogen bead capture system and PMCA that consistently detected vCJD prions from
clinical vCJD cases with 100% sensitivity and 100% diagnostic specificity was developed [18].
This test also demonstrated an ability to detect prions in blood plasma from two subclinical
blood donors (both 129MM); 1.3 and 2.6 years before clinical onset of disease. It is, however,
unknown whether this test can detect prions in the blood or plasma of individuals with other
codon 129 genotypes.
5. Determining risks to the individual and the population
The data from the Appendix studies indicate that up to 1 in 2,000 individuals in the UK may
be subclinical carriers of vCJD. Whether subclinical vCJD infection leads to clinical disease is
unknown and may depend on the recipient’s genotype, age, route, and/or level of infection. It
is also unknown whether the clinical manifestation of the disease will vary in different genetic
backgrounds and whether these individuals can transmit disease. The uncertainty surrounding
these issues can only be addressed by continued surveillance, appropriate risk management,
and the development of highly sensitive and specific markers of infection. To date, the only
evidence of transmission of vCJD between individuals is via blood transfusion.
Continued human surveillance is required in order to identify new cases of vCJD, to
promptly recognise any changes in clinical and/or pathological phenotype and to determine
whether there are other routes of secondary transmission. At present, a number of risk man-
agement strategies are in place to reduce the risk of human-to-human transmission through
blood. In the UK, these include leucoreduction of blood donations, donor deferral, and plasma
sourcing from abroad. The development of blood tests could aid in allowing screening of
blood donations or testing at-risk individuals. Concomitant with these approaches is a need to
continue research into determining the nature of infectivity and the level of infectivity
throughout the natural course of vCJD infection. It is essential that we do not become compla-
cent and continue both surveillance and risk management strategies in both human and ani-
mal prion diseases.
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